The gut bacterial community potentiates *Clostridioides difficile* infection severity.

Running title: Microbiota potentiates *Clostridioides difficile* infection severity

Nicholas A. Lesniak[1], Alyxandria M. Schubert[1], Kaitlyn J. Flynn[1], Jhansi L. Leslie[1,4], Hamide Sinani[1], Ingrid L. Bergin[3], Vincent B. Young[1,2], Patrick D. Schloss[1,†]

† To whom correspondence should be addressed: *pschloss@umich.edu*

1. Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

2. Division of Infectious Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI

3. Unit for Laboratory Animal Medicine, University of Michigan, Ann Arbor, MI

4. Current affiliation: Department of Medicine, Division of International Health and Infectious Diseases, University of Virginia School of Medicine, Charlottesville, Virginia, USA

Abstract

The severity of *Clostridioides difficile* infections (CDI) has increased over the last few decades. Patient age, white blood cell count, creatinine levels as well as *C. difficile* ribotype and toxin genes have been associated with disease severity. However, it is unclear whether specific members of the gut microbiota associate with variation in disease severity. The gut microbiota is known to interact with *C. difficile* during infection. Perturbations to the gut microbiota are necessary for *C. difficile* to colonize the gut. The gut microbiota can inhibit *C. difficile* colonization through bile acid metabolism, nutrient consumption and bacteriocin production. Here we sought to demonstrate that members of the gut bacterial communities can also contribute to disease severity. We derived diverse gut communities by colonizing germ-free mice with different human fecal communities. The mice were then infected with a single *C. difficile* ribotype 027 clinical isolate which resulted in moribundity and histopathologic differences. The variation in severity was associated with the human fecal community that the mice received. Generally, bacterial populations with pathogenic potential, such as *Enterococcus*, *Helicobacter*, and *Klebsiella*, were associated with more severe outcomes. Bacterial groups associated with fiber degradation and bile acid metabolism, such as *Anaerotignum*, *Blautia*, *Lactonifactor*, and *Monoglobus*, were associated with less severe outcomes. These data indicate that, in addition to the host and *C. difficile* subtype, populations of gut bacteria can influence CDI disease severity.

Importance

Clostridioides difficile colonization can be asymptomatic or develop into an infection, ranging in severity from mild diarrhea to toxic megacolon, sepsis, and death. Models that

predict severity and guide treatment decisions are based on clinical factors and *C. difficile* characteristics. Although the gut microbiome plays a role in protecting against CDI, its effect on CDI disease severity is unclear and has not been incorporated into disease severity models. We demonstrated that variation in the microbiome of mice colonized with human feces yielded a range of disease outcomes. These results revealed groups of bacteria associated with both severe and mild *C. difficile* infection outcomes. Gut bacterial community data from patients with CDI could improve our ability to identify patients at risk of developing more severe disease and improve interventions which target *C. difficile* and the gut bacteria to reduce host damage.

Introduction

Clostridioides difficile infections (CDI) have increased in incidence and severity since *C. difficile* was first identified as the cause of antibiotic-associated pseudomembranous colitis (1). CDI disease severity can range from mild diarrhea to toxic megacolon and death. The Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) guidelines define severe CDI in terms of a white blood cell count greater than 15,000 cells/mm^3 and/or a serum creatinine greater than 1.5 mg/dL. Patients who develop shock or hypotension, ileus, or toxic megacolon are considered to have fulminant CDI (2). Since these measures are CDI outcomes, they have limited ability to predict risk of severe CDI when the infection is first detected. Schemes have been developed to score a patient's risk for severe CDI outcomes based on clinical factors but have not been robust for broad application (3). Thus, we have limited ability to prevent patients from developing severe CDI.

Missing from CDI severity prediction models are the effects of the indigenous gut bacteria. *C. difficile* interacts with the gut community in many ways. The indigenous bacteria of a healthy intestinal community prevent *C. difficile* from infecting the gut (4). A range of mechanisms can disrupt this inhibition, including antibiotics, medications, or dietary changes, and lead to increased susceptibility to CDI (5–7). Once *C. difficile* overcomes the inhibition and colonizes the intestine, the indigenous bacteria can either promote or inhibit *C. difficile* through producing molecules or modifying the environment (8, 9). Bile acids metabolized by the gut bacteria can inhibit *C. difficile* growth and affect toxin production (4, 10, 11). Bacteria in the gut also can compete more directly with *C. difficile* through

antibiotic production or nutrient consumption (12–14). While the relationship between the gut bacteria and *C. difficile* has been established, the effect the gut bacteria can have on CDI disease severity is unclear.

Recent studies have demonstrated that when mice with diverse microbial communities were challenged with a high-toxigenic strain resulted in varied disease severity (15) and when challenged with a low-toxigenic strain members of the gut microbial community associated with variation in colonization (16). Here, we sought to further elucidate the relationship between members of the gut bacterial community and CDI disease severity when challenged with a high-toxigenic strain, *C. difficile* ribotype 027 (RT027). We hypothesized that since specific groups of gut bacteria affect the metabolism of *C. difficile* and its clearance rate, specific groups of bacteria associate with variation in CDI disease severity. To test this hypothesis, we colonized germ-free C57BL/6 mice with human fecal samples to create varied gut communities. We then challenged the mice with *C. difficile* RT027 and followed the mice for the development of severe outcomes of moribundity and histopathologic cecal tissue damage. Since the murine host and *C. difficile* isolate were the same and only the gut community varied, the variation in disease severity we observed was attributable to the gut microbiome.

Results

***C. difficile* is able to infect germ-free mice colonized with human fecal microbial communities without antibiotics.** To produce gut microbiomes with greater variation than those found in conventional mouse colonies, we colonized germ-free mice with bacteria from human feces (17). We inoculated germ-free C57BL/6 mice with homogenized

feces from each of 15 human fecal samples via oral gavage. These human fecal samples were selected because they represented diverse community structures based on community clustering (18). The gut communities were allowed to colonize for two weeks post-inoculation (19). We then surveyed the bacterial members of the gut communities by 16S rRNA gene sequencing of murine fecal pellets (Figure 1A). The bacterial communities from each mouse grouped more closely to those communities from mice that received the same human fecal donor community than to the mice who received a different human fecal donor community (Figure 1B). The communities were primarily composed of populations of *Clostridia*, *Bacteroidia*, *Erysipelotrichia*, *Bacilli*, and *Gammaproteobacteria*. However, the gut bacterial communities of each donor group of mice harbored unique relative abundance distributions of the shared bacterial classes.

Next, we tested this set of mice with their human-derived gut microbial communities for susceptibility to *C. difficile* infection. A typical mouse model of CDI requires pre-treatment of conventional mice with antibiotics, such as clindamycin, to become susceptible to *C. difficile* colonization (20, 21). However, we wanted to avoid modifying the gut communities with an antibiotic to maintain their unique microbial compositions and ecological relationships. Since some of these communities came from people at increased risk of CDI, such as recent hospitalization or antibiotic use (18), we tested whether *C. difficile* was able to infect these mice without an antibiotic perturbation. We hypothesized that *C. difficile* would be able to colonize the mice who received their gut communities from a donor with a perturbed community. Mice were challenged with 10^3 *C. difficile* RT027 clinical isolate spores. The mice were followed for 10 days post-challenge, and their stool was collected and plated for *C. difficile* colony forming units (CFU) to determine the extent of the

infection. Surprisingly, communities from all donors were able to be colonized (Figure 2). Two mice were able to resist *C. difficile* colonization, both received their community donor N1, which may be attributed to experimental variation since this group also had more mice. By colonizing germ-free mice with different human fecal communities, we were able to generate diverse gut communities in mice, which were susceptible to *C. difficile* infection without further modification of the gut community.

Infection severity varies by initial community. After we challenged the mice with *C. difficile*, we investigated the outcome from the infection and its relationship to the initial community. We followed the mice for 10 days post-challenge for colonization density, toxin production, and mortality. Seven mice, from Donors N1, N3, N4, and N5, were not colonized at detectable levels on the day after *C. difficile* challenge but were infected ($>10^6$) by the end of the experiment. All mice that received their community from Donor M1 through M6 succumbed to the infection and became moribund within 3 days post-challenge. The remaining mice, except the uninfected Donor N1 mice, maintained *C. difficile* infection through the end of the experiment (Figure 2). At 10 days post-challenge, or earlier for the moribund mice, mice were euthanised and fecal material were assayed for toxin activity and cecal tissue was collected and scored for histopathologic signs of disease (Figure 3). Overall, there was greater toxin activity detected in the stool of the moribund mice (Figure S1). However, when looking at each group of mice, we observed a range in toxin activity for both the moribund and non-moribund mice (Figure 3A). Non-moribund mice from Donors N2 and N5 through N9 had comparable toxin activity as the moribund mice at 2 days post-challenge. Additionally, not all moribund mice had toxin activity detected in their stool. Next, we examined the cecal tissue for histopathologic damage. Moribund mice had high

levels of epithelial damage, tissue edema, and inflammation (Figure S2) similar to previously reported histopathologic findings for *C. difficile* RT027 (22). As observed with toxin activity, the moribund mice had higher histopathologic scores than the non-moribund mice ($P < 0.001$). However, unlike the toxin activity, all moribund mice had consistently high histopathologic summary scores (Figure 3B). The non-moribund mice, Donor groups N1 through N9, had a range in tissue damage from none detected to similar levels as the moribund mice, which grouped by community donor. Together, the toxin activity, histopathologic score, and moribundity showed variation across the donor groups but were largely consistent within each donor group.

Microbial community members explain variation in CDI severity. We next interrogated the bacterial communities at the time of *C. difficile* challenge (day 0) for their relationship to infection outcomes using linear discriminant analysis (LDA) effect size (LEfSe) analysis to identify individual bacterial populations that could explain the variation in disease severity. We split the mice into groups by severity level based on moribundity or 10 days post infection (dpi) histopathologic score for non-moribund. This analysis revealed bacterial operational taxonomic units (OTUs) that were significantly different at the time of challenge by the disease severity (Figure 4A). OTUs associated with *Akkermansia*, *Bacteroides*, *Clostridium sensu stricto*, and *Turicibacter* were detected at higher relative abundances in the mice that became moribund. OTUs associated with *Anaerotignum*, *Enterocloster*, and *Murimonas* were more abundant in the non-moribund mice that would develop only low intestinal injury. To understand the role of toxin activity in disease severity, we applied LEfSe to identify the OTUs at the time of challenge that most likely explain the differences between communities that had toxin activity detected at anytime

point to those that did not (Figure 4B). An OTU associated with *Bacteroides*, OTU 7, associated with the presence of toxin also associated with moribundity. Likewise, OTUs associated with *Enterocloster* and *Murimonas* that were associated with no detected toxin also exhibited greater relative abundance in communities from non-moribund mice with a low histopathologic score. Lastly, we tested for correlations between the endpoint (10 dpi) relative abundances of OTUs and the histopathologic summary score (Figure 4C). The endpoint relative abundance of *Bacteroides*, OTU 17, was positively correlated with histopathologic score, as its day 0 relative abundance did with disease severity (Figure 4A). A population of *Bacteroides*, OTU 17, was positively correlated with the histopathologic score and were increased in the group of mice with detectable toxin. We also tested for correlations between the endpoint relative abundances of OTUs and toxin activity but none were significant. This analysis identified bacterial populations that were associated with the variation in moribundity, histopathologic score, and toxin.

We next determined whether, collectively, bacterial community membership and relative abundance could be predictive of the CDI disease outcome. We trained logistic regression models with bacterial community relative abundance data from the day of colonization at each taxonomic rank to predict toxin, moribundity, and histopathologic summary score. For predicting if detectable toxin would be produced, microbial populations aggregated by genus rank classification performed similarly as models using lower taxonomic ranks (mean AUROC = 0.787, Figure S3). *C. difficile* increased odds of producing detectable toxin when the community infected had less abundant populations of *Monoglobus*, *Akkermansia*, *Extibacter*, *Intestinimonas* and *Holdemania* and had more abundant populations of *Lachnospiraceae* (Figure 5A). Next, we assessed the ability of the community to predict

moribundity. Bacteria grouped by order rank classification was sufficient to predict which mice would succumb to the infection before the end of the experiment (mean AUROC = 0.9205, Figure S3). Many populations contributed to an increase odds of moribundity (Figure 5B). Populations related to *Bifidobacteriales* and *Clostridia* decreased the odds of a moribund outcome. Lastly, the relative abundances of OTUs were able to predict a high or low histopathologic score 10 dpi (histopathologic scores were dichotomized as in previous analysis, mean AUROC = 0.99, Figure S3). The model identified some similar OTUs as the LEfSe analysis, such as *Murimonas* (OTU 48), *Bacteroides* (OTU 7), and *Hungatella* (OTU 24). These models have shown that the relative abundance of bacterial populations and their relationship to each other could be used to predict the variation in moribundity, histopathologic score, and detectable toxin of CDI.

Discussion

Challenging mice colonized with different human fecal communities with *C. difficile* RT027 demonstrated that variation in members of the gut microbiome affects *C. difficile* infection disease severity. Our analysis revealed an association between the relative abundance of bacterial community members and disease severity. Previous studies investigating the severity of CDI disease involving the microbiome have had limited ability to interrogate this relationship between the microbiome and disease severity. Studies that have used clinical data have limited ability to control variation in the host, microbiome or *C. difficile* ribotype (23). Murine experiments typically use a single mouse colony and different *C. difficile* ribotypes to create severity differences (24). Recently, our group has begun uncovering the effect microbiome variation has on *C. difficile* infection. We showed the

variation in the bacterial communities between mice from different mouse colonies resulted in different clearance rates of *C. difficile* (16). We also showed varied ability of mice to spontaneously eliminate *C. difficile* infection when they were treated with different antibiotics prior to *C. difficile* challenge (25). Overall, the results presented here have demonstrated that the gut bacterial community contributed to the severity of *C. difficile* infection.

C. difficile can lead to asymptomatic colonization or infections with severity ranging from mild diarrhea to death. Physicians use classification tools to identify patients most at risk of developing a severe infection using white blood cell counts, serum albumin level, or serum creatinine level (2, 26, 27). Those levels are driven by the activities in the intestine (28). Research into the drivers of this variation have revealed factors that make *C. difficile* more virulent. Strains are categorized for their virulence by the presence and production of the toxins TcdA, TcdB, and binary toxin and the prevalence in outbreaks, such as ribotypes 027 and 078 (20, 29–32). However, other studies have shown that disease is not necessarily linked with toxin production (33) or the strain (34). Furthermore, there is variation in the genome, growth rate, sporulation, germination, and toxin production in different isolates of a strain (35–38). This variation may help explain why severe CDI prediction tools often miss identifying many patients with CDI that will develop severe disease (3, 24, 39, 40). Therefore, it is necessary to gain a full understanding of all factors contributing to disease variation to improve our ability to predict severity.

The state of the gut bacterial community determines the ability of *C. difficile* to colonize and persist in the intestine. *C. difficile* is unable to colonize an unperturbed healthy murine gut

community and is only able to become established after a perturbation (21). Once colonized, the different communities lead to different metabolic responses and dynamics of the *C. difficile* population (9, 25, 41). Gut bacteria metabolize primary bile acids into secondary bile acids (4, 42, 43). The concentration of these bile acids affects germination, growth, toxin production and biofilm formation (10, 11, 44, 45). Members of the bacterial community also affect other metabolites *C. difficile* utilizes. *Bacteroides thetaiotaomicron* produce sialidases which release sialic acid from the mucosa for *C. difficile* to utilize (46, 47). The nutrient environment affects toxin production (48). Thus, many of the actions of the gut bacteria modulate *C. difficile* in ways that could affect the infection and resultant disease.

A myriad of studies have explored the relationship between the microbiome and CDI disease. Studies examining difference in disease often use different *C. difficile* strains or ribotypes in mice with similar microbiota as a proxy for variation in disease, such as strain 630 for non-severe and RT027 for severe (20, 29, 30, 49). Studies have also demonstrated variation in infection through tapering antibiotic dosage (21, 25, 50) or by reducing the amount of *C. difficile* cells or spores used for the challenge (20, 50). These studies often either lack variation in the initial microbiome or have variation in the *C. difficile* infection itself, confounding any association between variation in severity and the microbiome. Recent studies have shown variation in the initial microbiome, via different murine colonies or colonizing germ-free mice with human feces, that were challenged with *C. difficile* resulted in varied outcomes of the infection (15, 16, 51).

Our data have demonstrated gut bacterial relative abundances associate with variation in toxin production, histopathologic scoring of the cecal tissue and mortality. This analysis revealed populations of *Akkermansia*, *Anaerotignum*, *Blautia*, *Enterocloster*, *Lactonifactor*, and *Monoglobus* were more abundant in the microbiome of non-moribund mice which had low histopathologic scores and no detected toxin. The protective role of these bacteria are supported by previous studies. *Blautia*, *Lactonifactor*, and *Monoglobus* have been shown to be involved in dietary fiber fermentation and associated with healthy communities (52–54). *Anaerotignum*, which produce short chain fatty acids, has been associated with healthy communities (55, 56). *Akkermansia* and *Enterocloster* were also identified as more abundant in mice which had a low histopathologic scores but have contradictory supporting evidence in the current literature. In our data, a population of *Akkermansia*, OTU 5, was most abundant in the non-moribund mice with low histopathologic scores but moribund mice had increased population of *Akkermansia*, OTU 8. This difference could indicate either a more protective mucus layer was present inhibiting colonization (57, 58) or mucus consumption by *Akkermansia* could have been crossfeeding *C. difficile* or exposing a niche for *C. difficile* (59–61). Similarly, *Enterocloster* was more abundant and associated with low histopathologic scores. It has been associated with healthy populations and has been used to mono-colonize germ-free mice to reduce the ability of *C. difficile* to colonize (62, 63). However, *Enterocloster* has also been involved in infections, such as bacteremia (64, 65). These data have exemplified populations of bacteria that have the potential to be either protective or harmful. Thus, the disease outcome is not likely based on the abundance of individual populations of bacteria, rather it is the result of the interactions of the community.

The groups of bacteria that were associated with either a higher histopathologic score or moribundity are members of the indigenous gut community that also have been associated with disease, often referred to as opportunistic pathogens. Some of the populations of *Bacteroides*, *Enterococcus*, and *Klebsiella* that associated with worse outcomes, have been shown to have pathogenic potential, expand after antibiotic use, and are commonly detected in CDI cases (66–69). In addition to these populations, *Eggerthella*, *Prevotellaceae* and *Helicobacter*, which associated with worse outcomes, have also been associated with intestinal inflammation (70–72). Recently, *Helicobacter hepaticus* was shown to be sufficient to cause susceptibility to CDI in IL-10 deficient C57BL/6 mice (73). In our experiments, when *Helicobacter* was present, the infection resulted in a high histopathologic score (Figure 4C). While we did not use IL-10 deficient mice, it is possible the bacterial community or host response are similarly modified by *Helicobacter*, allowing *C. difficile* infection and host damage. These bacteria groups increased in severe outcomes maintained their differences throughout the length of the experiment (Figure S4). These results agreed Aside from *Helicobacter*, these groups of bacteria that associated with more severe outcomes did not have a conserved association between their relative abundance and the disease severity across all mice.

Since we observed groups of bacteria that were associated with less severe disease it may be appropriate to apply the damage-response framework for microbial pathogenesis to CDI (74, 75). This framework posits that disease is not driven by a single entity, rather it is an emergent property of the responses of the host immune system, infecting microbe, *C. difficile*, and the indigenous microbes at the site of infection. In the first set of experiments, we used the same host background, C57BL/6 mice, the same infecting microbe, *C. difficile*

293 RT027 clinical isolate 431, with different gut bacterial communities. The bacterial groups
294 in those communities were often present in both moribund and non-moribund and across
295 the range of histopathologic scores. Thus, it was not merely the presence of the bacteria but
296 their activity in response to the other microbes and host which affect the extent of the host
297 damage. Additionally, while each mouse and *C. difficile* population had the same genetic
298 background, they too were reacting to the specific microbial community. Different gut
299 microbial communities can also have different effects on the host immune responses (76).
300 Disease severity is driven by the cumulative effect of the host immune response and the
301 activity of *C. difficile* and the gut bacteria. *C. difficile* drives host damage through the
302 production of toxin. The gut microbiota can modulate host damage through the balance of
303 metabolic and competitive interactions with *C. difficile*, such as bacteriocin production or
304 mucin degradation, and interactions with the host, such as host mucus glycosylation or
305 intestinal IL-33 expression (15, 77). For example, low levels of mucin degradation can
306 provide nutrients to other community members producing a diverse non-damaging
307 community (78). However, if mucin degradation becomes too great it reduces the
308 protective function of the mucin layer and exposes the epithelial cells. This over-harvesting
309 can contribute to the host damage due to other members producing toxin. Thus, the
310 resultant intestinal damage is the balance of all activities in the gut environment. Host
311 damage is the emergent property of numerous damage-response curves, such as one for
312 host immune response, one for *C. difficile* activity and another for microbiome community
313 activity, each of which are a composite curve of the individual activities from each group,
314 such as antibody production, neutrophil infiltration, toxin production, sporulation, fiber
315 and mucin degradation. Therefore, while we have identified populations of interest, it may

316 be necessary to target multiple types of bacteria to reduce the community interactions
317 contributing to host damage.

318 Here we have shown several bacterial groups and their relative abundances associated
319 with variation in CDI disease severity. Further understanding how the microbiome affects
320 severity in patients could reduce the amount of adverse CDI outcomes. When a patient is
321 diagnosed with CDI, the gut community composition, in addition to the traditionally
322 obtained clinical information, may improve our severity prediction and guide prophylactic
323 treatment. Treating the microbiome at the time of diagnosis, in addition to *C. difficile*, may
324 prevent the infection from becoming more severe.

325 Materials and Methods

326 **Animal care.** 6- to 13-week old male and female germ-free C57BL/6 were obtained from a
327 single breeding colony in the University of Michigan Germ-free Mouse Core. Mice (M1 n=3,
328 M2 n=3, M3 n=3, M4 n=3, M5 n=7, M6 n=3, N1 n=11, N2 n=7, N3 n=3, N4 n=3, N5 n=3, N6
329 n=3, N7 n=7, N8 n=3, N9 n=2) were housed in cages of 2-4 mice per cage and maintained in
330 germ-free isolators at the University of Michigan germ-free facility. All mouse experiments
331 were approved by the University Committee on Use and Care of Animals at the University
332 of Michigan.

333 ***C. difficile* experiments.** Human fecal samples were obtained as part of Schubert *et al.* and
334 selected based on community clusters (18) to result in diverse community structures
335 (Table S1). Feces were homogenized by mixing 200 mg of sample with 5 ml of PBS. Mice
336 were inoculated with 100 μl of the fecal homogenate via oral gavage. Two weeks after the
337 fecal community inoculation, mice were challenged with *C. difficile*. Stool samples from

each mouse were collected one day prior to *C. difficile* and plated for *C. difficile* enumeration to confirm no *C. difficile* was detected in stool prior to challenge. *C. difficile* clinical isolate 431 came from Carlson *et al.* which had previously been isolated and characterized (35, 36) and has recently been further characterized (37). Spores concentration were determined both before and after challenge (79). 10^3 *C. difficile* spores were given to each mouse via oral gavage.

Sample collection. Fecal samples were collected on the day of *C. difficile* challenge and the following 10 days. Each day, a fecal sample was collected and a portion was weighed for plating (approximately 30 mg) and the remaining sample was frozen at -20°C. Anaerobically, the weighed fecal samples were serially diluted in PBS, plated on TCCFA plates, and incubated at 37°C for 24 hours. The plates were then counted for the number of colony forming units (CFU) (80).

DNA sequencing. From the frozen fecal samples, total bacterial DNA was extracted using MOBIO PowerSoil-htp 96-well soil DNA isolation kit. We amplified the 16S rRNA gene V4 region and sequenced the resulting amplicons using an Illumina MiSeq as described previously (81).

Sequence curation. Sequences were processed with mothur(v.1.44.3) as previously described (81, 82). In short, we used a 3% dissimilarity cutoff to group sequences into operational taxonomic units (OTUs). We used a naive Bayesian classifier with the Ribosomal Database Project training set (version 18) to assign taxonomic classifications to each OTU (83). We sequenced a mock community of a known community composition and

16s rRNA gene sequences. We processed this mock community with our samples to calculate the error rate for our sequence curation, which was an error rate of 0.19%.

Toxin cytotoxicity assay. To prepare the sample for the activity assay, fecal material was diluted 1:10 weight per volume using sterile PBS and then filter sterilized through a 0.22-μm filter. Toxin activity was assessed using a Vero cell rounding-based cytotoxicity assay as described previously (30). The cytotoxicity titer was determined for each sample as the last dilution, which resulted in at least 80% cell rounding. Toxin titers are reported as the log10 of the reciprocal of the cytotoxicity titer.

Histopathology evaluation. Mouse cecal tissue was placed in histopathology cassettes and fixed in 10% formalin, then stored in 70% ethanol. McClinchey Histology Labs, Inc. (Stockbridge, MI) embedded the samples in paraffin, sectioned, and created the hematoxylin and eosin-stained slides. The slides were scored using previously described criteria by a board-certified veterinary pathologist who was blinded to the experimental groups (30). Slides were scored as 0-4 for parameters of epithelial damage, tissue edema, and inflammation and a summary score of 0-12 was generated by summing the three individual parameter scores. For non-moribund mice, histopathological summary scores used for LEfSe and logistic regression were split into high and low groups based on greater or less than the median summary score of 5 because the had a bimodal distribution ($P < 0.05$).

Statistical analysis and modeling. To compare community structures, we calculated Yue and Clayton dissimilarity matrices (θ_{YC}) in mothur (84). For this calculation, we averaged of 1000 sub-samples, or rarified, samples to 2,107 sequence reads per sample to limit uneven

sampling biases. We tested for differences in individual taxonomic groups that would explain the outcome differences with LEfSe (85) in mothur (default parameters, LDA > 4). We tested for differences in temporal trends through fitting a linear model to each OTU and testing for differences between histopathological summary scores with LEfSe (85) in mothur (default parameters, LDA > 3). Remaining statistical analysis and data visualization was performed in R (v4.0.5) with the tidyverse package (v1.3.1). We tested for significant differences in β-diversity (θ_{YC}), histopathological scores, and toxin activity using the Wilcoxon rank sum test, non-unimodality to non-moribund histopathological summary score using Hartigans' dip test, and toxin detection in mice using the Pearson's Chi-square test. We used Spearman's correlation to identify which OTUs that had a correlation between their relative abundance and the histopathologic summary score. *P* values were then corrected for multiple comparisons with a Benjamini and Hochberg adjustment for a type I error rate of 0.05 (86). We built L2 logistic regression models using the mikropml package (87). Sequence counts were summed by taxonomic ranks from day 0 samples, normalized by centering to the feature mean and scaling by the standard deviation, and features positively or negatively correlated were collapsed into a single feature. We ran our models using alpha = 0 and lambda values of 1e-0, 1e1, 1e2, 2e2, 3e2, 4e2, 5e2, 6e2, 7e2, 8e2, 9e2, 1e3, 1e4 with a split of 80% of the data for training and 20% of the data for testing. Lastly, we did not compare murine communities to donor community or clinical data because germ-free mice colonized with non-murine fecal communities have been shown to more closely resemble the murine communities than the donor species community (88). Furthermore, it is not our intention to make any inferences regarding human associated bacteria and their relationship with human CDI outcome.

Code availability. Scripts necessary to reproduce our analysis and this paper are available in an online repository (*https://github.com/SchlossLab/Lesniak_Severity_XXXX_2022*).

Sequence data accession number. All 16S rRNA gene sequence data and associated metadata are available through the Sequence Read Archive via accession PRJNA787941.

Acknowledgements

Thank you to Sarah Lucas and Sarah Tomkovich for critical discussion in the development and execution of this project. We also thank the University of Michigan Germ-free Mouse Core for assistance with our germfree mice, funded in part by U2CDK110768. This work was supported by several grants from the National Institutes for Health R01GM099514, U19AI090871, U01AI12455, and P30DK034933. Additionally, NAL was supported by the Molecular Mechanisms of Microbial Pathogenesis training grant (NIH T32 AI007528). The funding agencies had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Conceptualization: N.A.L., A.M.S., K.J.F., P.D.S.; Data curation: N.A.L., K.J.F.; Formal analysis: N.A.L., K.J.F., J.L.L., I.L.B.; Investigation: N.A.L., A.M.S., H.S., I.L.B., V.B.Y., P.D.S.; Methodology: N.A.L., A.M.S., K.J.F., J.L.L., H.S., I.L.B., V.B.Y., P.D.S.; Resources: N.A.L., A.M.S., P.D.S.; Software: NAL; Visualization: N.A.L., K.J.F., P.D.S.; Writing - original draft: N.A.L.; Writing - review & editing: N.A.L., A.M.S., K.J.F., J.L.L., H.S., I.L.B., V.B.Y., P.D.S.; Funding acquisition: V.B.Y.; Project administration: P.D.S.; Supervision: P.D.S.

References

1. **Kelly CP**, **LaMont JT**. 2008. *Clostridium difficile* — more difficult than ever. New England Journal of Medicine **359**:1932–1940. doi:*10.1056/nejmra0707500*.

2. **McDonald LC**, **Gerding DN**, **Johnson S**, **Bakken JS**, **Carroll KC**, **Coffin SE**, **Dubberke ER**, **Garey KW**, **Gould CV**, **Kelly C**, **Loo V**, **Sammons JS**, **Sandora TJ**, **Wilcox MH**. 2018. Clinical practice guidelines for *Clostridium difficile* infection in adults and children: 2017 update by the infectious diseases society of america (IDSA) and society for healthcare epidemiology of america (SHEA). Clinical Infectious Diseases **66**:e1–e48. doi:*10.1093/cid/cix1085*.

3. **Perry DA**, **Shirley D**, **Micic D**, **Patel CP**, **Putler R**, **Menon A**, **Young VB**, **Rao K**. 2021. External validation and comparison of *Clostridioides difficile* severity scoring systems. Clinical Infectious Diseases. doi:*10.1093/cid/ciab737*.

4. **Buffie CG**, **Bucci V**, **Stein RR**, **McKenney PT**, **Ling L**, **Gobourne A**, **No D**, **Liu H**, **Kinnebrew M**, **Viale A**, **Littmann E**, **Brink MRM van den**, **Jenq RR**, **Taur Y**, **Sander C**, **Cross JR**, **Toussaint NC**, **Xavier JB**, **Pamer EG**. 2014. Precision microbiome reconstitution restores bile acid mediated resistance to *Clostridium difficile*. Nature **517**:205–208. doi:*10.1038/nature13828*.

5. **Britton RA**, **Young VB**. 2014. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. Gastroenterology **146**:1547–1553. doi:*10.1053/j.gastro.2014.01.059*.

6. **Hryckowian AJ**, **Treuren WV**, **Smits SA**, **Davis NM**, **Gardner JO**, **Bouley DM**, **Sonnenburg JL**. 2018. Microbiota-accessible carbohydrates suppress *Clostridium difficile*

infection in a murine model. Nature Microbiology **3**:662–669. doi:*10.1038/s41564-018-0150-6*.

7. **Vila AV**, **Collij V**, **Sanna S**, **Sinha T**, **Imhann F**, **Bourgonje AR**, **Mujagic Z**, **Jonkers DMAE**, **Masclee AAM**, **Fu J**, **Kurilshikov A**, **Wijmenga C**, **Zhernakova A**, **Weersma RK**. 2020. Impact of commonly used drugs on the composition and metabolic function of the gut microbiota. Nature Communications **11**. doi:*10.1038/s41467-019-14177-z*.

8. **Abbas A**, **Zackular JP**. 2020. Microbe-microbe interactions during *Clostridioides difficile* infection. Current Opinion in Microbiology **53**:19–25. doi:*10.1016/j.mib.2020.01.016*.

9. **Jenior ML**, **Leslie JL**, **Young VB**, **Schloss PD**. 2017. *Clostridium difficile* colonizes alternative nutrient niches during infection across distinct murine gut microbiomes. mSystems **2**. doi:*10.1128/msystems.00063-17*.

10. **Sorg JA**, **Sonenshein AL**. 2008. Bile salts and glycine as cogerminants for *Clostridium difficile* spores. Journal of Bacteriology **190**:2505–2512. doi:*10.1128/jb.01765-07*.

11. **Thanissery R**, **Winston JA**, **Theriot CM**. 2017. Inhibition of spore germination, growth, and toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile acids. Anaerobe **45**:86–100. doi:*10.1016/j.anaerobe.2017.03.004*.

12. **Aguirre AM**, **Yalcinkaya N**, **Wu Q**, **Swennes A**, **Tessier ME**, **Roberts P**, **Miyajima F**, **Savidge T**, **Sorg JA**. 2021. Bile acid-independent protection against *Clostridioides difficile* infection. PLOS Pathogens **17**:e1010015. doi:*10.1371/journal.ppat.1010015*.

13. **Kang JD**, **Myers CJ**, **Harris SC**, **Kakiyama G**, **Lee I-K**, **Yun B-S**, **Matsuzaki K**, **Furukawa M**, **Min H-K**, **Bajaj JS**, **Zhou H**, **Hylemon PB**. 2019. Bile acid 7α-dehydroxylating gut

bacteria secrete antibiotics that inhibit *Clostridium difficile*: Role of secondary bile acids. Cell Chemical Biology **26**:27–34.e4. doi:*10.1016/j.chembiol.2018.10.003*.

14. **Leslie JL**, **Jenior ML**, **Vendrov KC**, **Standke AK**, **Barron MR**, **O'Brien TJ**, **Unverdorben L**, **Thaprawat P**, **Bergin IL**, **Schloss PD**, **Young VB**. 2021. Protection from lethal *Clostridioides difficile* infection via intraspecies competition for cogerminant. mBio **12**. doi:*10.1128/mbio.00522-21*.

15. **Nagao-Kitamoto H**, **Leslie JL**, **Kitamoto S**, **Jin C**, **Thomsson KA**, **Gillilland MG**, **Kuffa P**, **Goto Y**, **Jenq RR**, **Ishii C**, **Hirayama A**, **Seekatz AM**, **Martens EC**, **Eaton KA**, **Kao JY**, **Fukuda S**, **Higgins PDR**, **Karlsson NG**, **Young VB**, **Kamada N**. 2020. Interleukin-22-mediated host glycosylation prevents *Clostridioides difficile* infection by modulating the metabolic activity of the gut microbiota. Nature Medicine **26**:608–617. doi:*10.1038/s41591-020-0764-0*.

16. **Tomkovich S**, **Stough JMA**, **Bishop L**, **Schloss PD**. 2020. The initial gut microbiota and response to antibiotic perturbation influence *Clostridioides difficile* clearance in mice. mSphere **5**. doi:*10.1128/msphere.00869-20*.

17. **Nagpal R**, **Wang S**, **Woods LCS**, **Seshie O**, **Chung ST**, **Shively CA**, **Register TC**, **Craft S**, **McClain DA**, **Yadav H**. 2018. Comparative microbiome signatures and short-chain fatty acids in mouse, rat, non-human primate, and human feces. Frontiers in Microbiology **9**. doi:*10.3389/fmicb.2018.02897*.

18. **Schubert AM**, **Rogers MAM**, **Ring C**, **Mogle J**, **Petrosino JP**, **Young VB**, **Aronoff DM**, **Schloss PD**. 2014. Microbiome data distinguish patients with *Clostridium difficile* infection

and non-*C. difficile*-associated diarrhea from healthy controls. mBio **5**. doi:*10.1128/mbio.01021-14*.

19. **Gillilland MG**, **Erb-Downward JR**, **Bassis CM**, **Shen MC**, **Toews GB**, **Young VB**, **Huffnagle GB**. 2012. Ecological succession of bacterial communities during conventionalization of germ-free mice. Applied and Environmental Microbiology **78**:2359–2366. doi:*10.1128/aem.05239-11*.

20. **Chen X**, **Katchar K**, **Goldsmith JD**, **Nanthakumar N**, **Cheknis A**, **Gerding DN**, **Kelly CP**. 2008. A mouse model of *Clostridium difficile*-associated disease. Gastroenterology **135**:1984–1992. doi:*10.1053/j.gastro.2008.09.002*.

21. **Schubert AM**, **Sinani H**, **Schloss PD**. 2015. Antibiotic-induced alterations of the murine gut microbiota and subsequent effects on colonization resistance against *Clostridium difficile*. mBio **6**. doi:*10.1128/mbio.00974-15*.

22. **Cowardin CA**, **Buonomo EL**, **Saleh MM**, **Wilson MG**, **Burgess SL**, **Kuehne SA**, **Schwan C**, **Eichhoff AM**, **Koch-Nolte F**, **Lyras D**, **Aktories K**, **Minton NP**, **Petri WA**. 2016. The binary toxin CDT enhances *Clostridium difficile* virulence by suppressing protective colonic eosinophilia. Nature Microbiology **1**. doi:*10.1038/nmicrobiol.2016.108*.

23. **Seekatz AM**, **Rao K**, **Santhosh K**, **Young VB**. 2016. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent *Clostridium difficile* infection. Genome Medicine **8**. doi:*10.1186/s13073-016-0298-8*.

24. **Dieterle MG**, **Putler R**, **Perry DA**, **Menon A**, **Abernathy-Close L**, **Perlman NS**, **Penkevich A**, **Standke A**, **Keidan M**, **Vendrov KC**, **Bergin IL**, **Young VB**, **Rao K**. 2020.

508 Systemic inflammatory mediators are effective biomarkers for predicting adverse
509 outcomes in *Clostridioides difficile* infection. mBio **11**. doi:*10.1128/mbio.00180-20*.

510 25. **Lesniak NA**, **Schubert AM**, **Sinani H**, **Schloss PD**. 2021. Clearance of *Clostridioides*
511 *difficile* colonization is associated with antibiotic-specific bacterial changes. mSphere **6**.
512 doi:*10.1128/msphere.01238-20*.

513 26. **Lungulescu OA**, **Cao W**, **Gatskevich E**, **Tlhabano L**, **Stratidis JG**. 2011. CSI: A severity
514 index for *Clostridium difficile* infection at the time of admission. Journal of Hospital
515 Infection **79**:151–154. doi:*10.1016/j.jhin.2011.04.017*.

516 27. **Zar FA**, **Bakkanagari SR**, **Moorthi KMLST**, **Davis MB**. 2007. A comparison of
517 vancomycin and metronidazole for the treatment of *Clostridium difficile*-associated
518 diarrhea, stratified by disease severity. Clinical Infectious Diseases **45**:302–307.
519 doi:*10.1086/519265*.

520 28. **Masi A di**, **Leboffe L**, **Polticelli F**, **Tonon F**, **Zennaro C**, **Caterino M**, **Stano P**, **Fischer S**,
521 **Hägele M**, **Müller M**, **Kleger A**, **Papatheodorou P**, **Nocca G**, **Arcovito A**, **Gori A**, **Ruoppolo**
522 **M**, **Barth H**, **Petrosillo N**, **Ascenzi P**, **Bella SD**. 2018. Human serum albumin is an essential
523 component of the host defense mechanism against *Clostridium difficile* intoxication. The
524 Journal of Infectious Diseases **218**:1424–1435. doi:*10.1093/infdis/jiy338*.

525 29. **Abernathy-Close L**, **Dieterle MG**, **Vendrov KC**, **Bergin IL**, **Rao K**, **Young VB**. 2020.
526 Aging dampens the intestinal innate immune response during severe *Clostridioides difficile*
527 infection and is associated with altered cytokine levels and granulocyte mobilization.
528 Infection and Immunity **88**. doi:*10.1128/iai.00960-19*.

30. **Theriot CM**, **Koumpouras CC**, **Carlson PE**, **Bergin II**, **Aronoff DM**, **Young VB**. 2011. Cefoperazone-treated mice as an experimental platform to assess differential virulence of *Clostridium difficile* strains. Gut Microbes **2**:326–334. doi:*10.4161/gmic.19142*.

31. **Goorhuis A**, **Bakker D**, **Corver J**, **Debast SB**, **Harmanus C**, **Notermans DW**, **Bergwerff AA**, **Dekker FW**, **Kuijper EJ**. 2008. Emergence of *Clostridium difficile* infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clinical Infectious Diseases **47**:1162–1170. doi:*10.1086/592257*.

32. **O'Connor JR**, **Johnson S**, **Gerding DN**. 2009. *Clostridium difficile* infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology **136**:1913–1924. doi:*10.1053/j.gastro.2009.02.073*.

33. **Rao K**, **Micic D**, **Natarajan M**, **Winters S**, **Kiel MJ**, **Walk ST**, **Santhosh K**, **Mogle JA**, **Galecki AT**, **LeBar W**, **Higgins PDR**, **Young VB**, **Aronoff DM**. 2015. *Clostridium difficile* ribotype 027: Relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Clinical Infectious Diseases **61**:233–241. doi:*10.1093/cid/civ254*.

34. **Walk ST**, **Micic D**, **Jain R**, **Lo ES**, **Trivedi I**, **Liu EW**, **Almassalha LM**, **Ewing SA**, **Ring C**, **Galecki AT**, **Rogers MAM**, **Washer L**, **Newton DW**, **Malani PN**, **Young VB**, **Aronoff DM**. 2012. *Clostridium difficile* ribotype does not predict severe infection. Clinical Infectious Diseases **55**:1661–1668. doi:*10.1093/cid/cis786*.

35. **Carlson PE**, **Walk ST**, **Bourgis AET**, **Liu MW**, **Kopliku F**, **Lo E**, **Young VB**, **Aronoff DM**, **Hanna PC**. 2013. The relationship between phenotype, ribotype, and clinical disease in

human *Clostridium difficile* isolates. Anaerobe **24**:109–116. doi:*10.1016/j.anaerobe.2013.04.003*.

36. **Carlson PE**, **Kaiser AM**, **McColm SA**, **Bauer JM**, **Young VB**, **Aronoff DM**, **Hanna PC**. 2015. Variation in germination of *Clostridium difficile* clinical isolates correlates to disease severity. Anaerobe **33**:64–70. doi:*10.1016/j.anaerobe.2015.02.003*.

37. **Saund K**, **Pirani A**, **Lacy B**, **Hanna PC**, **Snitkin ES**. 2021. Strain variation in *Clostridioides difficile* toxin activity associated with genomic variation at both PaLoc and non-PaLoc loci. doi:*10.1101/2021.12.08.471880*.

38. **He M**, **Sebaihia M**, **Lawley TD**, **Stabler RA**, **Dawson LF**, **Martin MJ**, **Holt KE**, **Seth-Smith HMB**, **Quail MA**, **Rance R**, **Brooks K**, **Churcher C**, **Harris D**, **Bentley SD**, **Burrows C**, **Clark L**, **Corton C**, **Murray V**, **Rose G**, **Thurston S**, **Tonder A van**, **Walker D**, **Wren BW**, **Dougan G**, **Parkhill J**. 2010. Evolutionary dynamics of *Clostridium difficile* over short and long time scales. Proceedings of the National Academy of Sciences **107**:7527–7532. doi:*10.1073/pnas.0914322107*.

39. **Butt E**, **Foster JA**, **Keedwell E**, **Bell JE**, **Titball RW**, **Bhangu A**, **Michell SL**, **Sheridan R**. 2013. Derivation and validation of a simple, accurate and robust prediction rule for risk of mortality in patients with *Clostridium difficile* infection. BMC Infectious Diseases **13**. doi:*10.1186/1471-2334-13-316*.

40. **Beurden YH van**, **Hensgens MPM**, **Dekkers OM**, **Cessie SL**, **Mulder CJJ**, **Vandenbroucke-Grauls CMJE**. 2017. External validation of three prediction tools for patients at risk of a complicated course of *Clostridium difficile* infection: Disappointing in an

outbreak setting. Infection Control & Hospital Epidemiology **38**:897–905. doi:*10.1017/ice.2017.89*.

41. **Jenior ML**, **Leslie JL**, **Young VB**, **Schloss PD**. 2018. *Clostridium difficile* alters the structure and metabolism of distinct cecal microbiomes during initial infection to promote sustained colonization. mSphere **3**. doi:*10.1128/msphere.00261-18*.

42. **Staley C**, **Weingarden AR**, **Khoruts A**, **Sadowsky MJ**. 2016. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Applied Microbiology and Biotechnology **101**:47–64. doi:*10.1007/s00253-016-8006-6*.

43. **Long SL**, **Gahan CGM**, **Joyce SA**. 2017. Interactions between gut bacteria and bile in health and disease. Molecular Aspects of Medicine **56**:54–65. doi:*10.1016/j.mam.2017.06.002*.

44. **Sorg JA**, **Sonenshein AL**. 2010. Inhibiting the initiation of *Clostridium difficile* spore germination using analogs of chenodeoxycholic acid, a bile acid. Journal of Bacteriology **192**:4983–4990. doi:*10.1128/jb.00610-10*.

45. **Dubois T**, **Tremblay YDN**, **Hamiot A**, **Martin-Verstraete I**, **Deschamps J**, **Monot M**, **Briandet R**, **Dupuy B**. 2019. A microbiota-generated bile salt induces biofilm formation in *Clostridium difficile*. npj Biofilms and Microbiomes **5**. doi:*10.1038/s41522-019-0087-4*.

46. **Ng KM**, **Ferreyra JA**, **Higginbottom SK**, **Lynch JB**, **Kashyap PC**, **Gopinath S**, **Naidu N**, **Choudhury B**, **Weimer BC**, **Monack DM**, **Sonnenburg JL**. 2013. Microbiota-liberated host sugars facilitate post-antibiotic expansion of enteric pathogens. Nature **502**:96–99. doi:*10.1038/nature12503*.

47. **Ferreyra JA**, **Wu KJ**, **Hryckowian AJ**, **Bouley DM**, **Weimer BC**, **Sonnenburg JL**. 2014. Gut microbiota-produced succinate promotes *C. difficile* infection after antibiotic treatment or motility disturbance. Cell Host & Microbe **16**:770–777. doi:*10.1016/j.chom.2014.11.003*.

48. **Martin-Verstraete I**, **Peltier J**, **Dupuy B**. 2016. The regulatory networks that control *Clostridium difficile* toxin synthesis. Toxins **8**:153. doi:*10.3390/toxins8050153*.

49. **Lawley TD**, **Clare S**, **Walker AW**, **Stares MD**, **Connor TR**, **Raisen C**, **Goulding D**, **Rad R**, **Schreiber F**, **Brandt C**, **Deakin LJ**, **Pickard DJ**, **Duncan SH**, **Flint HJ**, **Clark TG**, **Parkhill J**, **Dougan G**. 2012. Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing *Clostridium difficile* disease in mice. PLoS Pathogens **8**:e1002995. doi:*10.1371/journal.ppat.1002995*.

50. **Reeves AE**, **Theriot CM**, **Bergin IL**, **Huffnagle GB**, **Schloss PD**, **Young VB**. 2011. The interplay between microbiome dynamics and pathogen dynamics in a murine model of *Clostridium difficile* infection. Gut Microbes **2**:145–158. doi:*10.4161/gmic.2.3.16333*.

51. **Battaglioli EJ**, **Hale VL**, **Chen J**, **Jeraldo P**, **Ruiz-Mojica C**, **Schmidt BA**, **Rekdal VM**, **Till LM**, **Huq L**, **Smits SA**, **Moor WJ**, **Jones-Hall Y**, **Smyrk T**, **Khanna S**, **Pardi DS**, **Grover M**, **Patel R**, **Chia N**, **Nelson H**, **Sonnenburg JL**, **Farrugia G**, **Kashyap PC**. 2018. *Clostridioides difficile* uses amino acids associated with gut microbial dysbiosis in a subset of patients with diarrhea. Science Translational Medicine **10**. doi:*10.1126/scitranslmed.aam7019*.

52. **Liu X**, **Mao B**, **Gu J**, **Wu J**, **Cui S**, **Wang G**, **Zhao J**, **Zhang H**, **Chen W**. 2021. *Blautia* — a new functional genus with potential probiotic properties? Gut Microbes **13**. doi:*10.1080/19490976.2021.1875796*.

53. **Mabrok HB**, **Klopfleisch R**, **Ghanem KZ**, **Clavel T**, **Blaut M**, **Loh G**. 2011. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis **33**:203–208. doi:*10.1093/carcin/bgr256*.

54. **Kim CC**, **Healey GR**, **Kelly WJ**, **Patchett ML**, **Jordens Z**, **Tannock GW**, **Sims IM**, **Bell TJ**, **Hedderley D**, **Henrissat B**, **Rosendale DI**. 2019. Genomic insights from *Monoglobus pectinilyticus*: A pectin-degrading specialist bacterium in the human colon. The ISME Journal **13**:1437–1456. doi:*10.1038/s41396-019-0363-6*.

55. **Choi S-H**, **Kim J-S**, **Park J-E**, **Lee KC**, **Eom MK**, **Oh BS**, **Yu SY**, **Kang SW**, **Han K-I**, **Suh MK**, **Lee DH**, **Yoon H**, **Kim B-Y**, **Lee JH**, **Lee JH**, **Lee J-S**, **Park S-H**. 2019. *Anaerotignum faecicola* sp. Nov., isolated from human faeces. Journal of Microbiology **57**:1073–1078. doi:*10.1007/s12275-019-9268-3*.

56. **Ueki A**, **Goto K**, **Ohtaki Y**, **Kaku N**, **Ueki K**. 2017. Description of *Anaerotignum aminivorans* gen. Nov., sp. Nov., a strictly anaerobic, amino-acid-decomposing bacterium isolated from a methanogenic reactor, and reclassification of *Clostridium propionicum*, *Clostridium neopropionicum* and *Clostridium lactatifermentans* as species of the genus *anaerotignum*. International Journal of Systematic and Evolutionary Microbiology **67**:4146–4153. doi:*10.1099/ijsem.0.002268*.

57. **Stein RR**, **Bucci V**, **Toussaint NC**, **Buffie CG**, **Rätsch G**, **Pamer EG**, **Sander C**, **Xavier JB**. 2013. Ecological modeling from time-series inference: Insight into dynamics and stability of intestinal microbiota. PLoS Computational Biology **9**:e1003388. doi:*10.1371/journal.pcbi.1003388*.

58. **Nakashima T**, **Fujii K**, **Seki T**, **Aoyama M**, **Azuma A**, **Kawasome H**. 2021. Novel gut microbiota modulator, which markedly increases *Akkermansia muciniphila* occupancy, ameliorates experimental colitis in rats. Digestive Diseases and Sciences. doi:*10.1007/s10620-021-07131-x*.

59. **Geerlings S**, **Kostopoulos I**, **Vos W de**, **Belzer C**. 2018. *Akkermansia muciniphila* in the human gastrointestinal tract: When, where, and how? Microorganisms **6**:75. doi:*10.3390/microorganisms6030075*.

60. **Deng H**, **Yang S**, **Zhang Y**, **Qian K**, **Zhang Z**, **Liu Y**, **Wang Y**, **Bai Y**, **Fan H**, **Zhao X**, **Zhi F**. 2018. *Bacteroides fragilis* prevents *Clostridium difficile* infection in a mouse model by restoring gut barrier and microbiome regulation. Frontiers in Microbiology **9**. doi:*10.3389/fmicb.2018.02976*.

61. **Engevik MA**, **Engevik AC**, **Engevik KA**, **Auchtung JM**, **Chang-Graham AL**, **Ruan W**, **Luna RA**, **Hyser JM**, **Spinler JK**, **Versalovic J**. 2020. Mucin-degrading microbes release monosaccharides that chemoattract *Clostridioides difficile* and facilitate colonization of the human intestinal mucus layer. ACS Infectious Diseases **7**:1126–1142. doi:*10.1021/acsinfecdis.0c00634*.

62. **Reeves AE**, **Koenigsknecht MJ**, **Bergin IL**, **Young VB**. 2012. Suppression of *Clostridium difficile* in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family *Lachnospiraceae*. Infection and Immunity **80**:3786–3794. doi:*10.1128/iai.00647-12*.

654 63. **Ma L**, **Keng J**, **Cheng M**, **Pan H**, **Feng B**, **Hu Y**, **Feng T**, **Yang F**. 2021. Gut microbiome
655 and serum metabolome alterations associated with isolated dystonia. mSphere **6**.
656 doi:*10.1128/msphere.00283-21*.

657 64. **Haas KN**, **Blanchard JL**. 2020. Reclassification of the *Clostridium clostridioforme* and
658 *Clostridium sphenoides* clades as *Enterocloster* gen. nov. And *Lacrimispora* gen. nov.,
659 Including reclassification of 15 taxa. International Journal of Systematic and Evolutionary
660 Microbiology **70**:23–34. doi:*10.1099/ijsem.0.003698*.

661 65. **Finegold SM**, **Song Y**, **Liu C**, **Hecht DW**, **Summanen P**, **Könönen E**, **Allen SD**. 2005.
662 *Clostridium clostridioforme*: A mixture of three clinically important species. European
663 Journal of Clinical Microbiology & Infectious Diseases **24**:319–324. doi:*10.1007/s10096-*
664 *005-1334-6*.

665 66. **Tomkovich S**, **Taylor A**, **King J**, **Colovas J**, **Bishop L**, **McBride K**, **Royzenblat S**,
666 **Lesniak NA**, **Bergin IL**, **Schloss PD**. 2021. An osmotic laxative renders mice susceptible to
667 prolonged *Clostridioides difficile* colonization and hinders clearance. mSphere **6**.
668 doi:*10.1128/msphere.00629-21*.

669 67. **Keith JW**, **Dong Q**, **Sorbara MT**, **Becattini S**, **Sia JK**, **Gjonbalaj M**, **Seok R**, **Leiner IM**,
670 **Littmann ER**, **Pamer EG**. 2020. Impact of antibiotic-resistant bacteria on immune
671 activation and *Clostridioides difficile* infection in the mouse intestine. Infection and
672 Immunity **88**. doi:*10.1128/iai.00362-19*.

673 68. **Zackular JP**, **Moore JL**, **Jordan AT**, **Juttukonda LJ**, **Noto MJ**, **Nicholson MR**, **Crews JD**,
674 **Semler MW**, **Zhang Y**, **Ware LB**, **Washington MK**, **Chazin WJ**, **Caprioli RM**, **Skaar EP**.

2016. Dietary zinc alters the microbiota and decreases resistance to *Clostridium difficile* infection. Nature Medicine **22**:1330–1334. doi:*10.1038/nm.4174*.

69. **Berkell M**, **Mysara M**, **Xavier BB**, **Werkhoven CH van**, **Monsieurs P**, **Lammens C**, **Ducher A**, **Vehreschild MJGT**, **Goossens H**, **Gunzburg J de**, **Bonten MJM**, **Malhotra-Kumar S**. 2021. Microbiota-based markers predictive of development of *Clostridioides difficile* infection. Nature Communications **12**. doi:*10.1038/s41467-021-22302-0*.

70. **Gardiner BJ**, **Tai AY**, **Kotsanas D**, **Francis MJ**, **Roberts SA**, **Ballard SA**, **Junckerstorff RK**, **Korman TM**. 2014. Clinical and microbiological characteristics of *Eggerthella lenta* bacteremia. Journal of Clinical Microbiology **53**:626–635. doi:*10.1128/jcm.02926-14*.

71. **Iljazovic A**, **Roy U**, **Gálvez EJC**, **Lesker TR**, **Zhao B**, **Gronow A**, **Amend L**, **Will SE**, **Hofmann JD**, **Pils MC**, **Schmidt-Hohagen K**, **Neumann-Schaal M**, **Strowig T**. 2020. Perturbation of the gut microbiome by *Prevotella* spp. enhances host susceptibility to mucosal inflammation. Mucosal Immunology **14**:113–124. doi:*10.1038/s41385-020-0296-4*.

72. **Nagalingam NA**, **Robinson CJ**, **Bergin IL**, **Eaton KA**, **Huffnagle GB**, **Young VB**. 2013. The effects of intestinal microbial community structure on disease manifestation in IL-$10^{-/-}$ mice infected with *Helicobacter hepaticus*. Microbiome **1**. doi:*10.1186/2049-2618-1-15*.

73. **Abernathy-Close L**, **Barron MR**, **George JM**, **Dieterle MG**, **Vendrov KC**, **Bergin IL**, **Young VB**. 2021. Intestinal inflammation and altered gut microbiota associated with inflammatory bowel disease render mice susceptible to *Clostridioides difficile* colonization and infection. mBio. doi:*10.1128/mbio.02733-20*.

74. **Pirofski L-a**, **Casadevall A**. 2008. The damage-response framework of microbial pathogenesis and infectious diseases, pp. 135–146. *In* Advances in experimental medicine and biology. Springer New York.

75. **Casadevall A**, **Pirofski L-a**. 2014. What is a host? Incorporating the microbiota into the damage-response framework. Infection and Immunity **83**:2–7. doi:*10.1128/iai.02627-14*.

76. **Lundberg R**, **Toft MF**, **Metzdorff SB**, **Hansen CHF**, **Licht TR**, **Bahl MI**, **Hansen AK**. 2020. Human microbiota-transplanted C57BL/6 mice and offspring display reduced establishment of key bacteria and reduced immune stimulation compared to mouse microbiota-transplantation. Scientific Reports **10**. doi:*10.1038/s41598-020-64703-z*.

77. **Frisbee AL**, **Saleh MM**, **Young MK**, **Leslie JL**, **Simpson ME**, **Abhyankar MM**, **Cowardin CA**, **Ma JZ**, **Pramoonjago P**, **Turner SD**, **Liou AP**, **Buonomo EL**, **Petri WA**. 2019. IL-33 drives group 2 innate lymphoid cell-mediated protection during *Clostridium difficile* infection. Nature Communications **10**. doi:*10.1038/s41467-019-10733-9*.

78. **Tailford LE**, **Crost EH**, **Kavanaugh D**, **Juge N**. 2015. Mucin glycan foraging in the human gut microbiome. Frontiers in Genetics **6**. doi:*10.3389/fgene.2015.00081*.

79. **Sorg JA**, **Dineen SS**. 2009. Laboratory maintenance of *Clostridium difficile*. Current Protocols in Microbiology **12**. doi:*10.1002/9780471729259.mc09a01s12*.

80. **Winston JA**, **Thanissery R**, **Montgomery SA**, **Theriot CM**. 2016. Cefoperazone-treated mouse model of clinically-relevant *Clostridium difficile* strain R20291. Journal of Visualized Experiments. doi:*10.3791/54850*.

81. **Kozich JJ**, **Westcott SL**, **Baxter NT**, **Highlander SK**, **Schloss PD**. 2013. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the MiSeq illumina sequencing platform. Applied and Environmental Microbiology **79**:5112–5120. doi:*10.1128/aem.01043-13*.

82. **Schloss PD**, **Westcott SL**, **Ryabin T**, **Hall JR**, **Hartmann M**, **Hollister EB**, **Lesniewski RA**, **Oakley BB**, **Parks DH**, **Robinson CJ**, **Sahl JW**, **Stres B**, **Thallinger GG**, **Horn DJV**, **Weber CF**. 2009. Introducing mothur: Open-source, platform-independent, community-supported software for describing and comparing microbial communities. Applied and Environmental Microbiology **75**:7537–7541. doi:*10.1128/aem.01541-09*.

83. **Wang Q**, **Garrity GM**, **Tiedje JM**, **Cole JR**. 2007. Naïve bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Applied and Environmental Microbiology **73**:5261–5267. doi:*10.1128/aem.00062-07*.

84. **Yue JC**, **Clayton MK**. 2005. A similarity measure based on species proportions. Communications in Statistics - Theory and Methods **34**:2123–2131. doi:*10.1080/sta-200066418*.

85. **Segata N**, **Izard J**, **Waldron L**, **Gevers D**, **Miropolsky L**, **Garrett WS**, **Huttenhower C**. 2011. Metagenomic biomarker discovery and explanation. Genome Biology **12**:R60. doi:*10.1186/gb-2011-12-6-r60*.

86. **Benjamini Y**, **Hochberg Y**. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Methodological) **57**:289–300. doi:*10.1111/j.2517-6161.1995.tb02031.x*.

87. **Topçuoğlu B**, **Lapp Z**, **Sovacool K**, **Snitkin E**, **Wiens J**, **Schloss P**. 2021. Mikropml: User-friendly R package for supervised machine learning pipelines. Journal of Open Source Software **6**:3073. doi:*10.21105/joss.03073*.

88. **Rawls JF**, **Mahowald MA**, **Ley RE**, **Gordon JI**. 2006. Reciprocal gut microbiota transplants from zebrafish and mice to germ-free recipients reveal host habitat selection. Cell **127**:423–433. doi:*10.1016/j.cell.2006.08.043*.

Figure 1. Human fecal microbial communities established diverse gut bacterial communities in germ-free mice. (A) Relative abundances of the 10 most abundant bacterial classes observed in the feces of previously germ-free C57Bl/6 mice 14 days post-colonization with human fecal samples (i.e., day 0 relative to *C. difficile* challenge). Each column of abundances represents an individual mouse. Mice that received the same donor feces are grouped together and labeled above with a letter (N for non-moribund mice and M for moribund mice) and number (ordered by mean histopathologic score of the donor group). + indicates the mice which did not have detectable *C. difficile* CFU (Figure 2). (B) Median (points) and interquartile range (lines) of β-diversity (θ_{YC}) between an individual mouse and either all others which were inoculated with feces from the same donor or from a different donor. The β-diversity among the same donor comparison group was significantly less than the β-diversity of either the different donor group or the donor community ($P < 0.05$, calculated by Wilcoxon rank sum test).

Figure 2. All donor groups resulted in *C. difficile* infection but with different outcomes. *C. difficile* CFU per gram of stool was measured the day after challenge with 10^3 *C. difficile* RT027 clinical isolate 431 spores and at the end of the experiment, 10 days post-challenge. Each point represents an individual mouse. Mice are grouped by donor and labeled by the donor letter (N for non-moribund mice and M for moribund mice) and number (ordered by mean histopathologic score of the donor group). Points are colored by donor group. Mice from donor groups N1 through N6 succumbed to the infection prior to day 10 and were not plated on day 10 post-challenge. LOD = Limit of detection. -Deceased- indicates mice were deceased at that time point so no sample was available.

Figure 3. Histopathologic score and toxin activity varied across donor groups. (A) Fecal toxin activity was detected in some mice post *C. difficile* challenge in both moribund and non-moribund mice. (B) Cecum scored for histopathologic damage from mice at the end of the experiment. Samples were collected for histopathologic scoring on day 10 post-challenge for non-moribund mice or the day the mouse succumbed to the infection for the moribund group (day 2 or 3 post-challenge). Each point represents an individual mouse. Mice are grouped by donor and labeled by the donor letter (N for non-moribund mice and M for moribund mice) and number (ordered by mean histopathologic score of the donor group). Points are colored by donor group. Mice in group N1 that have a summary score of 0 are the mice which did not have detectable *C. difficile* CFU (Figure 2). Missing points are from mice that had insufficient fecal sample collected for assaying toxin or cecum for histopathologic scoring. * indicates significant difference between non-moribund and moribund groups of mice by Wilcoxon test ($P < 0.002$). LOD = Limit of detection. -Deceased- indicates mice were deceased at that time point so no sample was available.

Figure 4. Individual fecal bacterial community members of the murine gut associated with *C .difficile* infection outcomes. (A and B) Relative abundance of OTUs at the time of *C. difficile* challenge (Day 0) that varied significantly by the moribundity and histopathologic summary score or detected toxin by LEfSe analysis. Median (points) and interquartile range (lines) are plotted. (A) Day 0 relative abundances were compared across infection outcome of moribund (colored black) or non-moribund with either a high histopathologic score (score greater than the median score of 5, colored green) or a low histopathologic summary score (score less than the median score of 5, colored light green). (B) Day 0 relative abundances were compared between mice which toxin activity was

789 detected (Toxin +, colored dark purple) and which no toxin activity was detected (Toxin -,
790 colored light purple). (C) Day 10 bacterial OTU relative abundances correlated with
791 histopathologic summary score. Each individual mouse is plotted and colored according to
792 their categorization in panel A. Points at the median score of 5 (gray points) were not
793 included in panel A. Spearman's correlations were statistically significant after Benjamini-
794 Hochberg correction for multiple comparisons. All bacterial groups are ordered by the LDA
795 score. * indicates that the bacterial group was unclassified at lower taxonomic classification
796 ranks.

797 **Figure 5. Fecal bacterial community members of the murine gut at the time of *C.***
798 ***difficile* infection predicted outcomes of the infection.** On the day of infection (Day 0),
799 bacterial community members grouped by different classification rank were modeled with
800 logistic regression to predict the infection outcome. The models used the highest taxonomic
801 classification rank without a decrease in performance. Models used all community
802 members but plotted are those members with a mean odds ratio not equal to 1. Median
803 (solid points) and interquartile range (lines) of the group relative abundance are plotted.
804 Bacterial groups are ordered by their odds ratio. * indicates that the bacterial group was
805 unclassified at lower taxonomic classification ranks. (A) Bacterial members grouped by
806 genus predicted which mice would have toxin activity detected at any point throughout the
807 infection (Toxin +, dark purple). (B) Bacterial members grouped by order predicted which
808 mice would become moribund (dark blue). (C) Bacterial members grouped by OTU
809 predicted if the mice would have a high (score greater than the median score of 5, colored
810 dark green) or low (score less than the median score of 5, colored light green)
811 histopathologic summary score.

Figure S1. Toxin detect in mice based on outcome of the infection. Comparison of the distribution of number of either non-moribund or moribund mice which toxin was detected in the first three days post infection. Bars are colored by whether toxin was detected in stool from the mouse (dark purple) or not (light purple). Moribund mice had significantly more mice with toxin detected ($P < 0.008$) by Pearson's Chi-square test.

Figure S2. Histopathologic score of tissue damage at the endpoint of the infection. Tissue collected at the endpoint, either day 10 post-challenge (Non-moribund) or day mice succumbed to infection (Moribund), were scored from histopathologic damage. Each point represents an individual mouse. Mice (points) are grouped and colored by their human fecal community donor. Missing points are from mice that had insufficient sample for histopathologic scoring. * indicates significant difference between non-moribund and moribund groups of mice by Wilcoxon test ($P < 0.002$).

Figure S3. Logistic regression models predicted outcomes of the *C. difficile* challenge. (A-C) Taxonomic classification rank model performance. Relative abundance at the time of *C. difficile* challenge (Day 0) of the bacterial community members grouped by different classification rank were modeled with random forest to predict the infection outcome. The models used the highest taxonomic classification rank performed as well as the lower ranks. Black rectangle highlights classification rank used to model each outcome. For all plots, median (large solid points), interquartile range (lines), and individual models (small transparent points) are plotted. (A) Toxin production modeled which mice would have toxin detected during the experiment. (B) Moribundity modeled which mice would succumb to the infection prior to day 10 post-challenge. (C) Histopathologic score modeled

834 which mice would have a high (score greater than the median score of 5) or low (score less
835 than the median score of 5) histopathologic summary score.

836 **Figure S4. Temporal dynamics of OTUs that differed between histopathologic**
837 **summary score.** Relative abundance of OTUs on each day relative to the time of *C. difficile*
838 challenge (Day 0) that have a significantly different temporal trend by the histopathologic
839 summary score by LEfSe analysis. Median (points) and interquartile range (lines) are
840 plotted. Points and lines are colored by infection outcome of moribund (colored black) or
841 non-moribund with either a high histopathologic score (score greater than the median
842 score of 5, colored green) or a low histopathologic summary score (score less than the
843 median score of 5, colored light green).